

Mometasone / Posaconazole / Gentamicin / Polymyxin B Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
9.0	28.09.2024	772739-00021	Date of first issue: 23.06.2016

SECTION 1. IDENTIFICATION

Product identifier : Mometasone / Posaconazole / Gentamicin / Polymyxin B Formulation

Manufacturer or supplier's details

Company : MSD

Address : Rua Coronel Bento Soares, 530
Cruzeiro - Sao Paulo - Brazil CEP 12730-340

Telephone : 908-740-4000

Emergency telephone : 1-908-423-6000

E-mail address : EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use

Recommended use : Veterinary product

Restrictions on use : Not applicable

SECTION 2. HAZARDS IDENTIFICATION**GHS Classification in accordance with ABNT NBR 14725 Standard**

Reproductive toxicity : Category 1A

Specific target organ toxicity - repeated exposure (Oral) : Category 2 (Kidney, inner ear)

Short-term (acute) aquatic hazard : Category 1

Long-term (chronic) aquatic hazard : Category 1

GHS label elements in accordance with ABNT NBR 14725 Standard

Hazard pictograms :



Signal Word : Danger

Hazard Statements : H360D May damage the unborn child.
H373 May cause damage to organs (Kidney, inner ear) through prolonged or repeated exposure if swallowed.
H410 Very toxic to aquatic life with long lasting effects.

**Mometasone / Posaconazole / Gentamicin /
Polymyxin B Formulation**Version
9.0Revision Date:
28.09.2024SDS Number:
772739-00021Date of last issue: 06.07.2024
Date of first issue: 23.06.2016**Precautionary Statements****Prevention:**

P201 Obtain special instructions before use.

P273 Avoid release to the environment.

P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

Response:

P308 + P313 IF exposed or concerned: Get medical advice/ attention.

P391 Collect spillage.

Storage:

P405 Store locked up.

Other hazards which do not result in classification

None known.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Classification	Concentration (% w/w)
Gentamicin	1403-66-3	Repr., 1A STOT RE, (Oral)(Kidney, inner ear) , 1 Aquatic Acute, 1 Aquatic Chronic, 1	≥ 1 -< 2,5
Posaconazole	171228-49-2	Eye Irrit., 2B Repr., 2 STOT RE, (Oral)(Adrenal gland, Bone marrow, Kidney, Liver, Nervous sys- tem, Reproductive organs) , 1 Aquatic Acute, 1 Aquatic Chronic, 1	$\geq 0,25$ -< 1
Mometasone	83919-23-7	Repr., 1B STOT RE, (Inhala- tion)(Immune system, Liver, Kidney, Skin) , 2 Aquatic Chronic, 1	$\geq 0,25$ -< 0,3
3-Mercaptopropane-1,2-diol	96-27-5	Acute Tox. (Oral), 4 Acute Tox. (Dermal), 3 Skin Irrit., 2 Eye Irrit., 2A Skin Sens., 1B	$\geq 0,1$ -< 0,25

**Mometasone / Posaconazole / Gentamicin /
Polymyxin B Formulation**

Version 9.0	Revision Date: 28.09.2024	SDS Number: 772739-00021	Date of last issue: 06.07.2024 Date of first issue: 23.06.2016
----------------	------------------------------	-----------------------------	---

		Aquatic Acute, 3	
--	--	------------------	--

SECTION 4. FIRST AID MEASURES

General advice	:	In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.
If inhaled	:	If inhaled, remove to fresh air. Get medical attention.
In case of skin contact	:	In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.
In case of eye contact	:	Flush eyes with water as a precaution. Get medical attention if irritation develops and persists.
If swallowed	:	If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water.
Most important symptoms and effects, both acute and delayed	:	May damage the unborn child. May cause damage to organs through prolonged or repeated exposure if swallowed.
Protection of first-aiders	:	First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
Notes to physician	:	Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media	:	Water spray Alcohol-resistant foam Carbon dioxide (CO ₂) Dry chemical
Unsuitable extinguishing media	:	None known.
Specific hazards during fire fighting	:	Exposure to combustion products may be a hazard to health.
Hazardous combustion products	:	Carbon oxides
Specific extinguishing methods	:	Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.

**Mometasone / Posaconazole / Gentamicin /
Polymyxin B Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
9.0	28.09.2024	772739-00021	Date of first issue: 23.06.2016

Special protective equipment : In the event of fire, wear self-contained breathing apparatus.
for fire-fighters Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Prevent spreading over a wide area (e.g., by containment or oil barriers).
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up : Soak up with inert absorbent material.
For large spills, provide diking or other appropriate containment to keep material from spreading. If diked material can be pumped, store recovered material in appropriate container.
Clean up remaining materials from spill with suitable absorbent.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

Technical measures : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust ventilation.

Advice on safe handling : Do not get on skin or clothing.
Do not breathe mist or vapors.
Do not swallow.
Avoid contact with eyes.
Wash skin thoroughly after handling.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
Keep container tightly closed.
Do not eat, drink or smoke when using this product.
Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working

Mometasone / Posaconazole / Gentamicin / Polymyxin B Formulation

Version 9.0 Revision Date: 28.09.2024 SDS Number: 772739-00021 Date of last issue: 06.07.2024
Date of first issue: 23.06.2016

- place.
When using do not eat, drink or smoke.
Wash contaminated clothing before re-use.
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.
- Conditions for safe storage : Keep in properly labeled containers.
Store locked up.
Keep tightly closed.
Store in accordance with the particular national regulations.
- Materials to avoid : Do not store with the following product types:
Strong oxidizing agents
Self-reactive substances and mixtures
Organic peroxides
Explosives
Gases

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Gentamicin	1403-66-3	TWA	0.1 mg/m ³ (OEB 2)	Internal
	Further information: OTO			
Posaconazole	171228-49-2	TWA	300 µg/m ³ (OEB 2)	Internal
Mometasone	83919-23-7	TWA	1 µg/m ³ (OEB 4)	Internal
	Further information: Skin			
		Wipe limit	10 µg/100 cm ²	Internal

- Engineering measures** : All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.
Essentially no open handling permitted.
Use closed processing systems or containment technologies.
If handled in a laboratory, use a properly designed biosafety cabinet, fume hood, or other containment device if the potential exists for aerosolization. If this potential does not exist, handle over lined trays or benchtops.

Personal protective equipment

- Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
- Filter type : Combined particulates and organic vapor type
- Hand protection

**Mometasone / Posaconazole / Gentamicin /
Polymyxin B Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
9.0	28.09.2024	772739-00021	Date of first issue: 23.06.2016

Material	:	Chemical-resistant gloves
Remarks	:	Consider double gloving.
Eye protection	:	Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
Skin and body protection	:	Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Physical state	:	liquid
Color	:	No data available
Odor	:	No data available
Odor Threshold	:	No data available
pH	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	No data available
Evaporation rate	:	No data available
Flammability (solid, gas)	:	Not applicable
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapor pressure	:	No data available
Relative vapor density	:	No data available
Relative density	:	No data available
Density	:	No data available

**Mometasone / Posaconazole / Gentamicin /
Polymyxin B Formulation**

Version 9.0	Revision Date: 28.09.2024	SDS Number: 772739-00021	Date of last issue: 06.07.2024 Date of first issue: 23.06.2016
----------------	------------------------------	-----------------------------	---

Solubility(ies)	
Water solubility	: No data available
Partition coefficient: n-octanol/water	: Not applicable
Autoignition temperature	: No data available
Decomposition temperature	: No data available
Viscosity	
Viscosity, kinematic	: No data available
Explosive properties	: Not explosive
Oxidizing properties	: The substance or mixture is not classified as oxidizing.
Molecular weight	: No data available
Particle characteristics	
Particle size	: Not applicable

SECTION 10. STABILITY AND REACTIVITY

Reactivity	: Not classified as a reactivity hazard.
Chemical stability	: Stable under normal conditions.
Possibility of hazardous reactions	: Can react with strong oxidizing agents.
Conditions to avoid	: None known.
Incompatible materials	: Oxidizing agents
Hazardous decomposition products	: No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure	: Inhalation Skin contact Ingestion Eye contact
--	--

Acute toxicity

Not classified based on available information.

Product:

Acute dermal toxicity	: Acute toxicity estimate: > 5.000 mg/kg Method: Calculation method
-----------------------	--

Components:**Gentamicin:**

Acute oral toxicity	: LD50 (Rat): 8.000 - 10.000 mg/kg
---------------------	------------------------------------

**Mometasone / Posaconazole / Gentamicin /
Polymyxin B Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
9.0	28.09.2024	772739-00021	Date of first issue: 23.06.2016

LD50 (Mouse): 10.000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 0,2 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist
Remarks: No mortality observed at this dose.

Acute toxicity (other routes of administration) : LD50 (Rat): 67 - 96 mg/kg
Application Route: Intravenous

LD50 (Rat): 371 - 384 mg/kg
Application Route: Intramuscular

LDLo (Monkey): 30 mg/kg
Application Route: Intravenous

Posaconazole:

Acute oral toxicity : LD50 (Rat): > 5.000 mg/kg

LD50 (Mouse): > 3.000 mg/kg

Acute dermal toxicity : LD50 (Rat): > 2.000 mg/kg

Mometasone:

Acute oral toxicity : LD50 (Rat): > 2.000 mg/kg

LD50 (Mouse): > 2.000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 3,3 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist
Remarks: No mortality observed at this dose.

LC50 (Mouse): > 3,2 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist

Acute toxicity (other routes of administration) : LD50 (Rat): 300 mg/kg
Application Route: Subcutaneous
Symptoms: Breathing difficulties

3-Mercaptopropane-1,2-diol:

Acute oral toxicity : LD50 (Rat): 648 mg/kg

Acute dermal toxicity : LD50 (Rabbit): 673 mg/kg

Skin corrosion/irritation

Not classified based on available information.

**Mometasone / Posaconazole / Gentamicin /
Polymyxin B Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
9.0	28.09.2024	772739-00021	Date of first issue: 23.06.2016

Components:**Gentamicin:**

Species	: Rabbit
Result	: Mild skin irritation

Posaconazole:

Species	: Rabbit
Result	: No skin irritation

Mometasone:

Species	: Rabbit
Result	: No skin irritation

3-Mercaptopropane-1,2-diol:

Species	: Rabbit
Result	: Skin irritation

Serious eye damage/eye irritation

Not classified based on available information.

Components:**Gentamicin:**

Species	: Rabbit
Result	: Mild eye irritation

Posaconazole:

Species	: Rabbit
Result	: Mild eye irritation

Mometasone:

Species	: Rabbit
Result	: No eye irritation

3-Mercaptopropane-1,2-diol:

Species	: Rabbit
Result	: Irritation to eyes, reversing within 21 days

Respiratory or skin sensitization**Skin sensitization**

Not classified based on available information.

Respiratory sensitization

Not classified based on available information.

**Mometasone / Posaconazole / Gentamicin /
Polymyxin B Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
9.0	28.09.2024	772739-00021	Date of first issue: 23.06.2016

Components:**Gentamicin:**

Remarks : No data available

Posaconazole:

Test Type : Magnusson-Kligman-Test
Routes of exposure : Skin contact
Species : Guinea pig
Result : negative

Mometasone:

Test Type : Maximization Test
Routes of exposure : Dermal
Species : Guinea pig
Assessment : Does not cause skin sensitization.
Result : negative
Remarks : The results of a test on guinea pigs showed this substance to be a weak skin sensitizer.

3-Mercaptopropane-1,2-diol:

Test Type : Local lymph node assay (LLNA)
Routes of exposure : Skin contact
Species : Mouse
Method : OECD Test Guideline 429
Result : positive

Assessment : Probability or evidence of low to moderate skin sensitization rate in humans

Germ cell mutagenicity

Not classified based on available information.

Components:**Gentamicin:**

Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test
Result: negative

Test Type: Chromosome aberration test in vitro
Result: equivocal

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
Species: Mouse
Application Route: Intravenous injection
Result: negative

Posaconazole:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

**Mometasone / Posaconazole / Gentamicin /
Polymyxin B Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
9.0	28.09.2024	772739-00021	Date of first issue: 23.06.2016

Genotoxicity in vivo	:	Result: negative
	:	Test Type: Chromosomal aberration
	:	Result: negative
	:	Test Type: Micronucleus test
	:	Species: Mouse
	:	Cell type: Bone marrow
	:	Application Route: Intravenous
	:	Result: negative

Mometasone:

Genotoxicity in vitro	:	Test Type: Bacterial reverse mutation assay (AMES)
	:	Result: negative
	:	Test Type: Chromosomal aberration
	:	Test system: Chinese hamster lung cells
	:	Result: negative
	:	Test Type: Chromosomal aberration
	:	Test system: Chinese hamster ovary cells
	:	Result: positive
	:	Test Type: Mouse Lymphoma
	:	Result: negative
Genotoxicity in vivo	:	Test Type: Micronucleus test
	:	Species: Mouse
	:	Application Route: Oral
	:	Result: negative
	:	Test Type: Chromosomal aberration
	:	Species: Rat
	:	Cell type: Bone marrow
	:	Result: negative
	:	Test Type: unscheduled DNA synthesis assay
	:	Species: Rat
	:	Cell type: Liver cells
	:	Result: negative
Germ cell mutagenicity - Assessment	:	Weight of evidence does not support classification as a germ cell mutagen.

3-Mercaptopropane-1,2-diol:

Genotoxicity in vitro	:	Test Type: Bacterial reverse mutation assay (AMES)
	:	Method: OECD Test Guideline 471
	:	Result: negative
	:	Remarks: Based on data from similar materials
	:	Test Type: In vitro mammalian cell gene mutation test
	:	Method: OECD Test Guideline 476

**Mometasone / Posaconazole / Gentamicin /
Polymyxin B Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
9.0	28.09.2024	772739-00021	Date of first issue: 23.06.2016

Result: negative
Remarks: Based on data from similar materials

Test Type: Chromosome aberration test in vitro
Method: OECD Test Guideline 473
Result: negative
Remarks: Based on data from similar materials

Carcinogenicity

Not classified based on available information.

Components:**Gentamicin:**

Carcinogenicity - Assessment : No data available

Posaconazole:

Species : Rat
Application Route : oral (feed)
Exposure time : 2 Years
Result : positive
Remarks : The mechanism or mode of action is not relevant in humans.

Species : Mouse
Application Route : Oral
Exposure time : 2 Years
Result : positive
Remarks : The mechanism or mode of action is not relevant in humans.

Mometasone:

Species : Rat
Application Route : Inhalation
Exposure time : 2 Years
Dose : 0.067 mg/kg body weight
Result : negative

Species : Mouse
Application Route : Inhalation
Exposure time : 19 Months
Dose : 0.160 mg/kg body weight
Result : negative

Reproductive toxicity

May damage the unborn child.

Components:**Gentamicin:**

Effects on fertility : Test Type: Two-generation reproduction toxicity study
Species: Rat
Fertility: NOAEL: 20 mg/kg body weight
Result: No significant adverse effects were reported

**Mometasone / Posaconazole / Gentamicin /
Polymyxin B Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
9.0	28.09.2024	772739-00021	Date of first issue: 23.06.2016

Effects on fetal development	:	Test Type: Embryo-fetal development Species: Rabbit Developmental Toxicity: NOAEL: 3,6 mg/kg body weight Result: No embryo-fetal toxicity.
		Test Type: Embryo-fetal development Species: Rat Application Route: Intraperitoneal Developmental Toxicity: LOAEL: 75 mg/kg body weight Result: Embryo-fetal toxicity.
		Test Type: Embryo-fetal development Species: Mouse Application Route: Intraperitoneal Developmental Toxicity: LOAEL: 10 mg/kg body weight Result: Fetal mortality., No malformations were observed.
		Test Type: Embryo-fetal development Species: Rat Application Route: Intraperitoneal Developmental Toxicity: LOAEL: 50 mg/kg body weight Result: Fetal mortality., No malformations were observed.
Reproductive toxicity - Assessment	:	Positive evidence of adverse effects on development from human epidemiological studies.

Posaconazole:

Effects on fertility	:	Test Type: Fertility/early embryonic development Species: Rat, male General Toxicity Parent: NOAEL: 180 mg/kg body weight Symptoms: No effects on mating performance. Result: negative
		Test Type: Fertility/early embryonic development Species: Rat, female General Toxicity Parent: NOAEL: 45 mg/kg body weight Symptoms: No effects on mating performance. Result: negative
Effects on fetal development	:	Test Type: Embryo-fetal development Species: Rat, female Application Route: Oral Developmental Toxicity: LOAEL: 29 mg/kg body weight Result: Fetotoxicity., Malformations were observed.
		Test Type: Embryo-fetal development Species: Rabbit, female Developmental Toxicity: LOAEL: 40 mg/kg body weight Result: Fetotoxicity.
Reproductive toxicity - Assessment	:	Some evidence of adverse effects on development, based on animal experiments.

**Mometasone / Posaconazole / Gentamicin /
Polymyxin B Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
9.0	28.09.2024	772739-00021	Date of first issue: 23.06.2016

II**Mometasone:**

- | | | |
|------------------------------------|---|---|
| Effects on fertility | : | Test Type: Fertility
Species: Rat
Application Route: Subcutaneous
Fertility: NOAEL: 0,015 mg/kg body weight
Symptoms: Reduced embryonic survival, Reduced fetal weight.
Result: No effects on fertility., Effect on reproduction capacity. |
| Effects on fetal development | : | Test Type: Embryo-fetal development
Species: Mouse
Application Route: Subcutaneous
Embryo-fetal toxicity.: LOAEL: 0,06 mg/kg body weight
Result: Embryotoxic effects., Teratogenicity and developmental toxicity

Test Type: Embryo-fetal development
Species: Rat
Application Route: Dermal
Embryo-fetal toxicity.: LOAEL: 0,3 mg/kg body weight
Result: Embryo-fetal toxicity.

Test Type: Embryo-fetal development
Species: Rabbit
Application Route: Dermal
Embryo-fetal toxicity.: LOAEL: 0,15 mg/kg body weight
Result: Embryo-fetal toxicity., Malformations were observed.

Test Type: Embryo-fetal development
Species: Rat
Application Route: Subcutaneous
Embryo-fetal toxicity.: LOAEL: 0,15 mg/kg body weight
Result: Effects on newborn.

Test Type: Embryo-fetal development
Species: Rabbit
Application Route: Oral
Embryo-fetal toxicity.: LOAEL: 0,7 mg/kg body weight
Result: Embryo-fetal toxicity., Malformations were observed. |
| Reproductive toxicity - Assessment | : | Clear evidence of adverse effects on development, based on animal experiments., Some evidence of adverse effects on sexual function and fertility, based on animal experiments. |

3-Mercaptopropane-1,2-diol:

- | | | |
|----------------------|---|---|
| Effects on fertility | : | Test Type: Two-generation reproduction toxicity study
Species: Rat
Application Route: Ingestion
Method: OECD Test Guideline 416
Result: negative
Remarks: Based on data from similar materials |
|----------------------|---|---|

**Mometasone / Posaconazole / Gentamicin /
Polymyxin B Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
9.0	28.09.2024	772739-00021	Date of first issue: 23.06.2016

Effects on fetal development : Test Type: Embryo-fetal development
Species: Rat
Application Route: Ingestion
Method: OECD Test Guideline 414
Result: negative
Remarks: Based on data from similar materials

STOT-single exposure

Not classified based on available information.

Components:**Mometasone:**

Remarks : Based on available data, the classification criteria are not met.

STOT-repeated exposure

May cause damage to organs (Kidney, inner ear) through prolonged or repeated exposure if swallowed.

Components:**Gentamicin:**

Target Organs : Kidney, inner ear
Assessment : Causes damage to organs through prolonged or repeated exposure.

Posaconazole:

Routes of exposure : Ingestion
Target Organs : Adrenal gland, Bone marrow, Kidney, Liver, Reproductive organs, Nervous system
Assessment : Causes damage to organs through prolonged or repeated exposure.

Mometasone:

Routes of exposure : inhalation (dust/mist/fume)
Target Organs : Immune system, Liver, Kidney, Skin
Assessment : May cause damage to organs through prolonged or repeated exposure.

Repeated dose toxicity**Components:****Gentamicin:**

Species : Dog
LOAEL : 3 mg/kg
Application Route : Intramuscular
Exposure time : 12 Months
Target Organs : Kidney

Mometasone / Posaconazole / Gentamicin / Polymyxin B Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
9.0	28.09.2024	772739-00021	Date of first issue: 23.06.2016

|| Symptoms : Vomiting, Salivation

|| Species : Monkey
 || LOAEL : 50 mg/kg
 || Application Route : Subcutaneous
 || Exposure time : 3 Weeks
 || Target Organs : Kidney, inner ear

|| Species : Monkey
 || LOAEL : 6 mg/kg
 || Application Route : Intramuscular
 || Exposure time : 3 Weeks
 || Target Organs : Blood, Kidney, inner ear, Liver

|| Species : Rat
 || NOAEL : 5 mg/kg
 || LOAEL : 10 mg/kg
 || Application Route : Intramuscular
 || Exposure time : 52 Weeks
 || Target Organs : Kidney, Blood

|| Species : Rat
 || NOAEL : 12,5 mg/kg
 || LOAEL : 50 mg/kg
 || Application Route : Intramuscular
 || Exposure time : 13 Weeks
 || Target Organs : Kidney

Posaconazole:

|| Species : Rat, female
 || LOAEL : 5 mg/kg
 || Application Route : Oral
 || Exposure time : 6 Months
 || Target Organs : Adrenal gland, Lungs, Heart, Liver, spleen, Kidney, Ovary

|| Species : Dog
 || LOAEL : 3 mg/kg
 || Application Route : Oral
 || Exposure time : 392 Days
 || Target Organs : Lungs, Liver, Brain, small intestine, Adrenal gland, Spinal cord, lymphoid tissue

|| Species : Monkey
 || LOAEL : 15 mg/kg
 || Application Route : Oral
 || Exposure time : 1 Months
 || Target Organs : Bone marrow, Adrenal gland, Lymph nodes, Blood

|| Species : Dog
 || LOAEL : 3 mg/kg
 || Application Route : Oral
 || Exposure time : 56 Weeks
 || Target Organs : Adrenal gland, Bone marrow, Kidney, Nervous system,

Mometasone / Posaconazole / Gentamicin / Polymyxin B Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
9.0	28.09.2024	772739-00021	Date of first issue: 23.06.2016

|| spleen, thymus gland, Testis, lymphoid tissue

|| Species : Monkey
 || LOAEL : 180 mg/kg
 || Application Route : Oral
 || Exposure time : 12 Months
 || Target Organs : Blood, Gastrointestinal tract, spleen

|| Species : Monkey
 || LOAEL : 8 mg/kg
 || Application Route : Intravenous
 || Exposure time : 1 Months
 || Target Organs : Cardio-vascular system, Lungs, Adrenal gland, Blood

Mometasone:

|| Species : Rat
 || NOAEL : 0,005 mg/kg
 || LOAEL : 0,3 mg/kg
 || Application Route : Oral
 || Exposure time : 30 d
 || Target Organs : Lymph nodes, Liver, Adrenal gland, Skin, thymus gland

|| Species : Dog
 || LOAEL : 0,5 mg/kg
 || Application Route : Oral
 || Exposure time : 30 d
 || Target Organs : Lymph nodes, Liver, Adrenal gland, Skin, thymus gland

|| Species : Rat
 || NOAEL : 0,00013 mg/l
 || Application Route : inhalation (dust/mist/fume)
 || Exposure time : 90 d
 || Target Organs : Adrenal gland, Lungs, Lymph nodes, spleen, Bone marrow, Kidney, Liver, thymus gland

|| Species : Dog
 || NOAEL : 0,0005 mg/l
 || Application Route : inhalation (dust/mist/fume)
 || Exposure time : 90 d
 || Target Organs : Adrenal gland, Lungs, Lymph nodes, spleen, Bone marrow, Kidney, thymus gland, Liver

3-Mercaptopropane-1,2-diol:

|| Species : Rat
 || LOAEL : > 100 mg/kg
 || Application Route : Ingestion
 || Exposure time : 55 Days
 || Method : OECD Test Guideline 422
 || Remarks : Based on data from similar materials

**Mometasone / Posaconazole / Gentamicin /
Polymyxin B Formulation**

Version 9.0	Revision Date: 28.09.2024	SDS Number: 772739-00021	Date of last issue: 06.07.2024 Date of first issue: 23.06.2016
----------------	------------------------------	-----------------------------	---

Aspiration toxicity

Not classified based on available information.

Components:**Mometasone:**

|| Not applicable

Experience with human exposure**Components:****Gentamicin:**

Ingestion	:	Target Organs: Kidney Target Organs: inner ear Symptoms: Dizziness, Vertigo, hearing loss, tinnitus, fetal deafness
-----------	---	---

Posaconazole:

Ingestion	:	Symptoms: Cough, Headache, Nausea, Vomiting, Fever, Liver effects, Rash, pruritis, Diarrhea, hypertension, neutropenia, electrolyte imbalance
-----------	---	---

Mometasone:

Inhalation	:	Symptoms: allergic rhinitis, Headache, pharyngitis, upper respiratory tract infection, sinusitis, oral candidiasis, Back pain, musculoskeletal pain, immune system effects, indigestion
Skin contact	:	Symptoms: Dermatitis, Itching

Further information**Components:****Mometasone:**

Remarks	:	Dermal absorption possible
---------	---	----------------------------

SECTION 12. ECOLOGICAL INFORMATION**Ecotoxicity****Components:****Gentamicin:**

Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Daphnia magna (Water flea)): 86 mg/l Exposure time: 48 h Method: OECD Test Guideline 202 LC50 (Americamysis): 30 mg/l Exposure time: 96 h Method: US-EPA OPPTS 850.1035
Toxicity to algae/aquatic plants	:	EC50 (Pseudokirchneriella subcapitata (green algae)): 10 µg/l Exposure time: 72 h

Mometasone / Posaconazole / Gentamicin / Polymyxin B Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
9.0	28.09.2024	772739-00021	Date of first issue: 23.06.2016

	Method: OECD Test Guideline 201
	NOEC (Pseudokirchneriella subcapitata (green algae)): 1,5 µg/l
	Exposure time: 72 h
	Method: OECD Test Guideline 201
	EC50 (Anabaena flos-aquae (cyanobacterium)): 4,7 µg/l
	Exposure time: 72 h
	Method: OECD Test Guideline 201
	NOEC (Anabaena flos-aquae (cyanobacterium)): 1,6 µg/l
	Exposure time: 72 h
	Method: OECD Test Guideline 201
M-Factor (Acute aquatic toxicity)	: 100
M-Factor (Chronic aquatic toxicity)	: 1
Toxicity to microorganisms	: EC50: 288,7 mg/l
	Exposure time: 3 h
	Test Type: Respiration inhibition
	Method: OECD Test Guideline 209

Posaconazole:

Toxicity to fish	: LC50 (Oncorhynchus mykiss (rainbow trout)): > 0,95 mg/l
	Exposure time: 96 h
	Method: OECD Test Guideline 203
	Remarks: No toxicity at the limit of solubility.
Toxicity to daphnia and other aquatic invertebrates	: EC50 (Daphnia magna (Water flea)): 0,276 mg/l
	Exposure time: 48 h
	Method: OECD Test Guideline 202
Toxicity to algae/aquatic plants	: EC50 (Pseudokirchneriella subcapitata (green algae)): > 0,509 mg/l
	Exposure time: 72 h
	Method: OECD Test Guideline 201
	NOEC (Pseudokirchneriella subcapitata (green algae)): 0,041 mg/l
	Exposure time: 72 h
	Method: OECD Test Guideline 201
M-Factor (Acute aquatic toxicity)	: 1
Toxicity to fish (Chronic toxicity)	: NOEC (Pimephales promelas (fathead minnow)): 0,206 mg/l
	Exposure time: 33 d
	Method: OECD Test Guideline 210
Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)	: NOEC (Daphnia magna (Water flea)): 0,244 mg/l
	Exposure time: 21 d
	Method: OECD Test Guideline 211

Mometasone / Posaconazole / Gentamicin / Polymyxin B Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
9.0	28.09.2024	772739-00021	Date of first issue: 23.06.2016

Remarks: No toxicity at the limit of solubility.

M-Factor (Chronic aquatic toxicity) : 1

Toxicity to microorganisms : EC50 (Natural microorganism): > 1.000 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

Mometasone:

Toxicity to fish : LC50 (Menidia beryllina (Silverside)): 0,11 mg/l
Exposure time: 96 h
Remarks: No toxicity at the limit of solubility.

LC50 (Cyprinodon variegatus (sheepshead minnow)): > 5 mg/l
Exposure time: 7 d
Remarks: No toxicity at the limit of solubility.

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 5 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202
Remarks: No toxicity at the limit of solubility.

EC50 (Americamysis): > 5 mg/l
Exposure time: 96 h
Method: US-EPA OPPTS 850.1035
Remarks: No toxicity at the limit of solubility.

Toxicity to algae/aquatic plants : EC50 (Pseudokirchneriella subcapitata (green algae)): > 3,2 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201
Remarks: No toxicity at the limit of solubility.

Toxicity to fish (Chronic toxicity) : NOEC (Pimephales promelas (fathead minnow)): 0,00014 mg/l
Exposure time: 32 d
Method: OECD Test Guideline 210

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 0,34 mg/l
Exposure time: 21 d
Method: OECD Test Guideline 211
Remarks: No toxicity at the limit of solubility.

M-Factor (Chronic aquatic toxicity) : 100

Toxicity to microorganisms : EC50: > 1.000 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209
Remarks: No toxicity at the limit of solubility.

NOEC: 1.000 mg/l

Mometasone / Posaconazole / Gentamicin / Polymyxin B Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
9.0	28.09.2024	772739-00021	Date of first issue: 23.06.2016

Exposure time: 3 h
 Test Type: Respiration inhibition
 Method: OECD Test Guideline 209
 Remarks: No toxicity at the limit of solubility.

3-Mercaptopropane-1,2-diol:

Toxicity to fish	:	LC50 (Oncorhynchus mykiss (rainbow trout)): > 10 - 100 mg/l Exposure time: 96 h Method: OECD Test Guideline 203 Remarks: Based on data from similar materials
Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Daphnia magna (Water flea)): > 10 - 100 mg/l Exposure time: 48 h Method: OECD Test Guideline 202 Remarks: Based on data from similar materials
Toxicity to algae/aquatic plants	:	ErC50 (Raphidocelis subcapitata (freshwater green alga)): > 10 - 100 mg/l Exposure time: 72 h Method: OECD Test Guideline 201 Remarks: Based on data from similar materials
		EC10 (Raphidocelis subcapitata (freshwater green alga)): > 1 mg/l Exposure time: 72 h Method: OECD Test Guideline 201 Remarks: Based on data from similar materials
Toxicity to microorganisms	:	EC10 (activated sludge): > 1 mg/l Exposure time: 3 h Method: OECD Test Guideline 209 Remarks: Based on data from similar materials

Persistence and degradability

Components:

Gentamicin:

Biodegradability	:	Result: rapidly degradable Biodegradation: 100 % Exposure time: 28 d Method: OECD Test Guideline 314
------------------	---	---

Posaconazole:

Biodegradability	:	Result: Not readily biodegradable. Biodegradation: 50 % Exposure time: 28 h Method: OECD Test Guideline 314
Stability in water	:	Degradation half life (DT50): > 30 d Method: OECD Test Guideline 111

**Mometasone / Posaconazole / Gentamicin /
Polymyxin B Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
9.0	28.09.2024	772739-00021	Date of first issue: 23.06.2016

Mometasone:

Biodegradability	: Result: Not readily biodegradable. Biodegradation: 50 % Exposure time: 28 d Method: OECD Test Guideline 314
Stability in water	: Hydrolysis: 50 %(12 d) Method: OECD Test Guideline 111

3-Mercaptopropane-1,2-diol:

Biodegradability	: Result: Readily biodegradable. Remarks: Based on data from similar materials
------------------	---

Bioaccumulative potential**Components:****Gentamicin:**

Partition coefficient: n-octanol/water	: log Pow: < -2
--	-----------------

Posaconazole:

Bioaccumulation	: Species: Lepomis macrochirus (Bluegill sunfish) Bioconcentration factor (BCF): 20 Method: OECD Test Guideline 305
Partition coefficient: n-octanol/water	: log Pow: 4,15

Mometasone:

Bioaccumulation	: Species: Lepomis macrochirus (Bluegill sunfish) Bioconcentration factor (BCF): 107,1 Method: OECD Test Guideline 305
Partition coefficient: n-octanol/water	: log Pow: 4,68

3-Mercaptopropane-1,2-diol:

Partition coefficient: n-octanol/water	: log Pow: -0,84 Method: OECD Test Guideline 117
--	---

Mobility in soil**Components:****Posaconazole:**

Distribution among environmental compartments	: log Koc: 5,52
---	-----------------

Mometasone:

Distribution among environmental compartments	: log Koc: 4,02
---	-----------------

**Mometasone / Posaconazole / Gentamicin /
Polymyxin B Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
9.0	28.09.2024	772739-00021	Date of first issue: 23.06.2016

Other adverse effects

No data available

SECTION 13. DISPOSAL CONSIDERATIONS**Disposal methods**

Waste from residues	:	Do not dispose of waste into sewer. Dispose of in accordance with local regulations.
Contaminated packaging	:	Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION**International Regulations****UNRTDG**

UN number	:	UN 3082
Proper shipping name	:	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (Gentamicin, Mometasone)
Class	:	9
Packing group	:	III
Labels	:	9
Environmentally hazardous	:	yes

IATA-DGR

UN/ID No.	:	UN 3082
Proper shipping name	:	Environmentally hazardous substance, liquid, n.o.s. (Gentamicin, Mometasone)
Class	:	9
Packing group	:	III
Labels	:	Miscellaneous
Packing instruction (cargo aircraft)	:	964
Packing instruction (passen- ger aircraft)	:	964
Environmentally hazardous	:	yes

IMDG-Code

UN number	:	UN 3082
Proper shipping name	:	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (Gentamicin, Mometasone)
Class	:	9
Packing group	:	III
Labels	:	9
EmS Code	:	F-A, S-F
Marine pollutant	:	yes

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

Domestic regulation

**Mometasone / Posaconazole / Gentamicin /
Polymyxin B Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
9.0	28.09.2024	772739-00021	Date of first issue: 23.06.2016

ANTT

UN number	:	UN 3082
Proper shipping name	:	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (Gentamicin, Mometasone)
Class	:	9
Packing group	:	III
Labels	:	9
Hazard Identification Number	:	90

Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

SECTION 15. REGULATORY INFORMATION**Safety, health and environmental regulations/legislation specific for the substance or mixture**

National List of Carcinogenic Agents for Humans - (LINACH) : Not applicable

Brazil. List of chemicals controlled by the Federal Police : Not applicable

The ingredients of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

SECTION 16. OTHER INFORMATION

Revision Date	:	28.09.2024
Date format	:	dd.mm.yyyy

Further information

Sources of key data used to compile the Material Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Full text of other abbreviations

**Mometasone / Posaconazole / Gentamicin /
Polymyxin B Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
9.0	28.09.2024	772739-00021	Date of first issue: 23.06.2016

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

BR / Z8